The Delay of Tolvaptan-induced Liver Injury in an Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patient: A Case Report-Reference-Cited by-同舟云学术

The Delay of Tolvaptan-induced Liver Injury in an Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patient: A Case Report

Published:2021-02-01 Issue:2 Volume:62 Page:72-79
ISSN:0451-4203
Container-title:Kanzo
language:en
Short-container-title:Acta hepatologica Japonica

Author:

Sasaki Reina¹,Kanda Tatsuo¹,Honda Masayuki¹,Takahashi Hiroshi¹,Kaneko Tomohiro¹,Yamana Yoichiro¹,Kumagawa Mariko¹,Ishii Tomotaka¹,Mizutani Taku¹,Masuzaki Ryota¹,Nirei Kazushige¹,Yamagami Hiroaki¹,Matsumoto Naoki¹,Moriyama Mitsuhiko¹

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

https://www.jstage.jst.go.jp/article/kanzo/62/2/62_72/_pdf

Reference17 articles.

1. 2) Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418

2. 4) Khan MY, Rawala MS, Siddiqui M, et al. Tolvaptan-induced Liver Injury: Who is at Risk? A Case Report and Literature Review. Cureus 2019; 11: 4842

3. 5) Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf 2015; 38: 1103-1113

4. 6) Wu Y, Beland FA, Chen S, et al. Mechanisms of tolvaptan-induced toxicity in HepG2 cells. Biochem Pharmacol 2015; 95: 324-336

5. 7) Mosedale M, Kim Y, Brock WJ, et al. Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach. Toxicol Sci 2017; 156: 438-454

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tolvaptan;Reactions Weekly;2021-05